In addition to evaluating GATA4 as a potential prognostic factor, we characterized the expression levels of HER2-4, as well as gene copy numbers of HER2 in GCTs and correlated the expression levels to tumor recurrence and survival in a cohort of 80 GCT patients. The gene discussed is ERBB2; the disease is neoplasm.